Volume 14 Supplement 1
Publication charges for this supplement were funded by 3P Solution, Milan, Italy. PAA has acted in a consultant/advisory role for BMS, Roche-Genentech, MSD, Ventana, Novartis and Amgen and has received research funding from BMS, Roche-Genentech and Ventana. The other Supplement Editors declare that they have no competing interests.
Naples, Italy1-5 December 2015
Edited by Paolo A Ascierto, Francesco M Marincola and Nicolar Mozzillo.
MELANOMA BRIDGE 2015
Citation Impact
5.531 - 2-year Impact Factor
5.760 - 5-year Impact Factor
1.244 - Source Normalized Impact per Paper (SNIP)
1.576 - SCImago Journal Rank (SJR)
Speed
8 days to first decision for all manuscripts
60 days to first decision for reviewed manuscripts only
115 days from submission to acceptance
13 days from acceptance to publication
Usage
4,155,992 Downloads (2021)
3,471 mentions